Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer
Identifieur interne : 003998 ( PascalFrancis/Checkpoint ); précédent : 003997; suivant : 003999Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer
Auteurs : Mattias Johansson [Suède] ; James D. Mckay [France, Australie] ; P R Stattin [Suède] ; Federico Canzian [France, Allemagne] ; Catherine Boillot [France] ; Fredrik Wiklund [Suède] ; Hans-Olov Adami [Suède, États-Unis] ; Katarina B Lter [Suède] ; Henrik Grönberg [Suède] ; Rudolf Kaaks [France, Allemagne]Source :
- International journal of cancer [ 0020-7136 ] ; 2007.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Insulin-like growth factor-I (IGF1) stimulates cell proliferation, decreases apoptosis, and has been implicated in cancer development. Epidemiological studies have shown elevated levels of circulating IGF1 to be associated with increased risk of prostate cancer. To what extent genetic variation in the IGF1 gene is related to prostate cancer risk is largely unknown. We performed a comprehensive haplotype tagging (HT) assessment of single nucleotide polymorphisms (SNPs) representing the common haplotype variation in the IGF1 gene. We genotyped 10 SNPs (9 haplotype tagging SNPs (htSNPs)) within Cancer Prostate in Sweden (CAPS), a case-control study of 2,863 cases and 1,737 controls, in order to investigate if genetic variation in the IGF1 gene is associated with prostate cancer risk. Three haplotype blocks were identified across the IGF1 gene and 9 SNPs were selected as haplotype tagging SNPs. Common haplotypes in the block covering the 3' region of the IGF1 gene showed significant global association with prostate cancer risk (p = 0.004), with one particular haplotype giving an odds ratio of 1.46 (95% CI = 1.15-1.84, p = 0.002). This haplotype had a prevalence of 5% in the study population. Our results indicate that common variation in the IGF1 gene, particularly in the 3' region, may affect prostate cancer risk. Further studies on genetic variations in the IGF1 gene in relation to prostate cancer risk as well as to circulating levels of IGF1 are needed to confirm this novel finding.
Affiliations:
- Allemagne, Australie, France, Suède, États-Unis
- Auvergne-Rhône-Alpes, Bade-Wurtemberg, District de Karlsruhe, Massachusetts, Rhône-Alpes, Svealand
- Cambridge (Massachusetts), Heidelberg, Lyon, Stockholm
- Université Harvard
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:07-0071430Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer</title><author><name sortKey="Johansson, Mattias" sort="Johansson, Mattias" uniqKey="Johansson M" first="Mattias" last="Johansson">Mattias Johansson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume? University Hospital</s1><s2>Ume?</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Ume?</wicri:noRegion></affiliation></author><author><name sortKey="Mckay, James D" sort="Mckay, James D" uniqKey="Mckay J" first="James D." last="Mckay">James D. Mckay</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Menzies Research Institute</s1><s2>Hohart, Tasmania</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Menzies Research Institute</wicri:noRegion></affiliation></author><author><name sortKey="Stattin, P R" sort="Stattin, P R" uniqKey="Stattin P" first="P R" last="Stattin">P R Stattin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume? University Hospital</s1><s2>Ume?</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Ume?</wicri:noRegion></affiliation></author><author><name sortKey="Canzian, Federico" sort="Canzian, Federico" uniqKey="Canzian F" first="Federico" last="Canzian">Federico Canzian</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Genomic Epidemiology Group, German Cancer Institute (DKFZ)</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Boillot, Catherine" sort="Boillot, Catherine" uniqKey="Boillot C" first="Catherine" last="Boillot">Catherine Boillot</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Wiklund, Fredrik" sort="Wiklund, Fredrik" uniqKey="Wiklund F" first="Fredrik" last="Wiklund">Fredrik Wiklund</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Adami, Hans Olov" sort="Adami, Hans Olov" uniqKey="Adami H" first="Hans-Olov" last="Adami">Hans-Olov Adami</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Department of Epidemiology, Harvard University</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Cambridge (Massachusetts)</settlement><region type="state">Massachusetts</region></placeName><orgName type="university">Université Harvard</orgName></affiliation></author><author><name sortKey="B Lter, Katarina" sort="B Lter, Katarina" uniqKey="B Lter K" first="Katarina" last="B Lter">Katarina B Lter</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Gronberg, Henrik" sort="Gronberg, Henrik" uniqKey="Gronberg H" first="Henrik" last="Grönberg">Henrik Grönberg</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Kaaks, Rudolf" sort="Kaaks, Rudolf" uniqKey="Kaaks R" first="Rudolf" last="Kaaks">Rudolf Kaaks</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ)</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0071430</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0071430 INIST</idno><idno type="RBID">Pascal:07-0071430</idno><idno type="wicri:Area/PascalFrancis/Corpus">003E36</idno><idno type="wicri:Area/PascalFrancis/Curation">002252</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003998</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003998</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer</title><author><name sortKey="Johansson, Mattias" sort="Johansson, Mattias" uniqKey="Johansson M" first="Mattias" last="Johansson">Mattias Johansson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume? University Hospital</s1><s2>Ume?</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Ume?</wicri:noRegion></affiliation></author><author><name sortKey="Mckay, James D" sort="Mckay, James D" uniqKey="Mckay J" first="James D." last="Mckay">James D. Mckay</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Menzies Research Institute</s1><s2>Hohart, Tasmania</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Menzies Research Institute</wicri:noRegion></affiliation></author><author><name sortKey="Stattin, P R" sort="Stattin, P R" uniqKey="Stattin P" first="P R" last="Stattin">P R Stattin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume? University Hospital</s1><s2>Ume?</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Ume?</wicri:noRegion></affiliation></author><author><name sortKey="Canzian, Federico" sort="Canzian, Federico" uniqKey="Canzian F" first="Federico" last="Canzian">Federico Canzian</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Genomic Epidemiology Group, German Cancer Institute (DKFZ)</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Boillot, Catherine" sort="Boillot, Catherine" uniqKey="Boillot C" first="Catherine" last="Boillot">Catherine Boillot</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Wiklund, Fredrik" sort="Wiklund, Fredrik" uniqKey="Wiklund F" first="Fredrik" last="Wiklund">Fredrik Wiklund</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Adami, Hans Olov" sort="Adami, Hans Olov" uniqKey="Adami H" first="Hans-Olov" last="Adami">Hans-Olov Adami</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Department of Epidemiology, Harvard University</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Cambridge (Massachusetts)</settlement><region type="state">Massachusetts</region></placeName><orgName type="university">Université Harvard</orgName></affiliation></author><author><name sortKey="B Lter, Katarina" sort="B Lter, Katarina" uniqKey="B Lter K" first="Katarina" last="B Lter">Katarina B Lter</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Gronberg, Henrik" sort="Gronberg, Henrik" uniqKey="Gronberg H" first="Henrik" last="Grönberg">Henrik Grönberg</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Kaaks, Rudolf" sort="Kaaks, Rudolf" uniqKey="Kaaks R" first="Rudolf" last="Kaaks">Rudolf Kaaks</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ)</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">International journal of cancer</title><title level="j" type="abbreviated">Int. j. cancer</title><idno type="ISSN">0020-7136</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">International journal of cancer</title><title level="j" type="abbreviated">Int. j. cancer</title><idno type="ISSN">0020-7136</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancerology</term><term>Case control study</term><term>Epidemiology</term><term>Gene</term><term>Genetic variability</term><term>Genotype</term><term>Haplotype</term><term>Human</term><term>Insulin like growth factor 1</term><term>Nephrology</term><term>Prostate cancer</term><term>Risk factor</term><term>Single nucleotide polymorphism</term><term>Sweden</term><term>Urology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer prostate</term><term>Variabilité génétique</term><term>Gène</term><term>Facteur croissance IGF1</term><term>Génotype</term><term>Facteur risque</term><term>Epidémiologie</term><term>Polymorphisme mononucléotide</term><term>Haplotype</term><term>Cancérologie</term><term>Etude cas témoin</term><term>Suède</term><term>Urologie</term><term>Homme</term><term>Néphrologie</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Suède</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Insulin-like growth factor-I (IGF1) stimulates cell proliferation, decreases apoptosis, and has been implicated in cancer development. Epidemiological studies have shown elevated levels of circulating IGF1 to be associated with increased risk of prostate cancer. To what extent genetic variation in the IGF1 gene is related to prostate cancer risk is largely unknown. We performed a comprehensive haplotype tagging (HT) assessment of single nucleotide polymorphisms (SNPs) representing the common haplotype variation in the IGF1 gene. We genotyped 10 SNPs (9 haplotype tagging SNPs (htSNPs)) within Cancer Prostate in Sweden (CAPS), a case-control study of 2,863 cases and 1,737 controls, in order to investigate if genetic variation in the IGF1 gene is associated with prostate cancer risk. Three haplotype blocks were identified across the IGF1 gene and 9 SNPs were selected as haplotype tagging SNPs. Common haplotypes in the block covering the 3' region of the IGF1 gene showed significant global association with prostate cancer risk (p = 0.004), with one particular haplotype giving an odds ratio of 1.46 (95% CI = 1.15-1.84, p = 0.002). This haplotype had a prevalence of 5% in the study population. Our results indicate that common variation in the IGF1 gene, particularly in the 3' region, may affect prostate cancer risk. Further studies on genetic variations in the IGF1 gene in relation to prostate cancer risk as well as to circulating levels of IGF1 are needed to confirm this novel finding.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0020-7136</s0></fA01><fA02 i1="01"><s0>IJCNAW</s0></fA02><fA03 i2="1"><s0>Int. j. cancer</s0></fA03><fA05><s2>120</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer</s1></fA08><fA11 i1="01" i2="1"><s1>JOHANSSON (Mattias)</s1></fA11><fA11 i1="02" i2="1"><s1>MCKAY (James D.)</s1></fA11><fA11 i1="03" i2="1"><s1>STATTIN (Pär)</s1></fA11><fA11 i1="04" i2="1"><s1>CANZIAN (Federico)</s1></fA11><fA11 i1="05" i2="1"><s1>BOILLOT (Catherine)</s1></fA11><fA11 i1="06" i2="1"><s1>WIKLUND (Fredrik)</s1></fA11><fA11 i1="07" i2="1"><s1>ADAMI (Hans-Olov)</s1></fA11><fA11 i1="08" i2="1"><s1>BÄLTER (Katarina)</s1></fA11><fA11 i1="09" i2="1"><s1>GRÖNBERG (Henrik)</s1></fA11><fA11 i1="10" i2="1"><s1>KAAKS (Rudolf)</s1></fA11><fA14 i1="01"><s1>Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume? University Hospital</s1><s2>Ume?</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="03"><s1>Menzies Research Institute</s1><s2>Hohart, Tasmania</s2><s3>AUS</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Genomic Epidemiology Group, German Cancer Institute (DKFZ)</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1><s2>Stockholm</s2><s3>SWE</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Epidemiology, Harvard University</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ)</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>10 aut.</sZ></fA14><fA20><s1>539-542</s1></fA20><fA21><s1>2007</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>13027</s2><s5>354000145145420120</s5></fA43><fA44><s0>0000</s0><s1>© 2007 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>24 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>07-0071430</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>International journal of cancer</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Insulin-like growth factor-I (IGF1) stimulates cell proliferation, decreases apoptosis, and has been implicated in cancer development. Epidemiological studies have shown elevated levels of circulating IGF1 to be associated with increased risk of prostate cancer. To what extent genetic variation in the IGF1 gene is related to prostate cancer risk is largely unknown. We performed a comprehensive haplotype tagging (HT) assessment of single nucleotide polymorphisms (SNPs) representing the common haplotype variation in the IGF1 gene. We genotyped 10 SNPs (9 haplotype tagging SNPs (htSNPs)) within Cancer Prostate in Sweden (CAPS), a case-control study of 2,863 cases and 1,737 controls, in order to investigate if genetic variation in the IGF1 gene is associated with prostate cancer risk. Three haplotype blocks were identified across the IGF1 gene and 9 SNPs were selected as haplotype tagging SNPs. Common haplotypes in the block covering the 3' region of the IGF1 gene showed significant global association with prostate cancer risk (p = 0.004), with one particular haplotype giving an odds ratio of 1.46 (95% CI = 1.15-1.84, p = 0.002). This haplotype had a prevalence of 5% in the study population. Our results indicate that common variation in the IGF1 gene, particularly in the 3' region, may affect prostate cancer risk. Further studies on genetic variations in the IGF1 gene in relation to prostate cancer risk as well as to circulating levels of IGF1 are needed to confirm this novel finding.</s0></fC01><fC02 i1="01" i2="X"><s0>002B04</s0></fC02><fC02 i1="02" i2="X"><s0>002B14D01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Cancer prostate</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Prostate cancer</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Cáncer de la próstata</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Variabilité génétique</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Genetic variability</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Variabilidad genética</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Gène</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Gene</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Gen</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Facteur croissance IGF1</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Insulin like growth factor 1</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Factor crecimiento IGF1</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Génotype</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Genotype</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Genotipo</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Facteur risque</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Risk factor</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Epidémiologie</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Epidemiology</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Epidemiología</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Polymorphisme mononucléotide</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Single nucleotide polymorphism</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Polimorfismo mononucleótido</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Haplotype</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Haplotype</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Haplotipo</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancérologie</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Cancerology</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cancerología</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Etude cas témoin</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Case control study</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Estudio caso control</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Suède</s0><s2>NG</s2><s5>18</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Sweden</s0><s2>NG</s2><s5>18</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Suecia</s0><s2>NG</s2><s5>18</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Urologie</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Urology</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Urología</s0><s5>19</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Néphrologie</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Nephrology</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Nefrología</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Appareil génital mâle pathologie</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Male genital diseases</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Aparato genital macho patología</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Appareil urinaire pathologie</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Urinary system disease</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Aparato urinario patología</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Prostate pathologie</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Génétique</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Genetics</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Genética</s0><s5>41</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Santé publique</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Public health</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Salud pública</s0><s5>42</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Facteur croissance</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Growth factor</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Factor crecimiento</s0><s5>43</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Polypeptide</s0><s5>45</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Polypeptide</s0><s5>45</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Polipéptido</s0><s5>45</s5></fC07><fN21><s1>043</s1></fN21></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Suède</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li><li>Massachusetts</li><li>Rhône-Alpes</li><li>Svealand</li></region><settlement><li>Cambridge (Massachusetts)</li><li>Heidelberg</li><li>Lyon</li><li>Stockholm</li></settlement><orgName><li>Université Harvard</li></orgName></list><tree><country name="Suède"><noRegion><name sortKey="Johansson, Mattias" sort="Johansson, Mattias" uniqKey="Johansson M" first="Mattias" last="Johansson">Mattias Johansson</name></noRegion><name sortKey="Adami, Hans Olov" sort="Adami, Hans Olov" uniqKey="Adami H" first="Hans-Olov" last="Adami">Hans-Olov Adami</name><name sortKey="B Lter, Katarina" sort="B Lter, Katarina" uniqKey="B Lter K" first="Katarina" last="B Lter">Katarina B Lter</name><name sortKey="Gronberg, Henrik" sort="Gronberg, Henrik" uniqKey="Gronberg H" first="Henrik" last="Grönberg">Henrik Grönberg</name><name sortKey="Stattin, P R" sort="Stattin, P R" uniqKey="Stattin P" first="P R" last="Stattin">P R Stattin</name><name sortKey="Wiklund, Fredrik" sort="Wiklund, Fredrik" uniqKey="Wiklund F" first="Fredrik" last="Wiklund">Fredrik Wiklund</name></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Mckay, James D" sort="Mckay, James D" uniqKey="Mckay J" first="James D." last="Mckay">James D. Mckay</name></region><name sortKey="Boillot, Catherine" sort="Boillot, Catherine" uniqKey="Boillot C" first="Catherine" last="Boillot">Catherine Boillot</name><name sortKey="Canzian, Federico" sort="Canzian, Federico" uniqKey="Canzian F" first="Federico" last="Canzian">Federico Canzian</name><name sortKey="Kaaks, Rudolf" sort="Kaaks, Rudolf" uniqKey="Kaaks R" first="Rudolf" last="Kaaks">Rudolf Kaaks</name></country><country name="Australie"><noRegion><name sortKey="Mckay, James D" sort="Mckay, James D" uniqKey="Mckay J" first="James D." last="Mckay">James D. Mckay</name></noRegion></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Canzian, Federico" sort="Canzian, Federico" uniqKey="Canzian F" first="Federico" last="Canzian">Federico Canzian</name></region><name sortKey="Kaaks, Rudolf" sort="Kaaks, Rudolf" uniqKey="Kaaks R" first="Rudolf" last="Kaaks">Rudolf Kaaks</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Adami, Hans Olov" sort="Adami, Hans Olov" uniqKey="Adami H" first="Hans-Olov" last="Adami">Hans-Olov Adami</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003998 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 003998 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:07-0071430
|texte= Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer
}}
| This area was generated with Dilib version V0.6.33. |  |